Q-omics provides the consensus-scored SYT16 profile across patient tissues and cancer cell-line models. SYT16 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, SYT16 is differentially expressed in 11, with the highest sampling consensus in HNSC. Additionally, SYT16 RNA expression shows 16,185 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, HNSC, and TGCT as cancer lineages where SYT16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SYT16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SYT16 survival associations across molecular data types. SYT16 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (6) and mass-spec protein abundance (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SYT16 RNA expression–survival associations across cancer types. High SYT16 expression shows unfavorable associations in UCEC, UVM, LUAD, CESC, LIHC and STAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCEC as the clearest survival context for SYT16 RNA expression.
This table summarizes SYT16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SYT16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SYT16 shows lower tumor expression in THCA and KIRC and higher tumor expression in HNSC, BLCA, KIRP and LUAD. The HNSC box plot shows higher SYT16 RNA expression in tumor versus normal tissue (log2 FC = +0.172, t-test p < 0.001).
This table shows molecular features associated with SYT16 in patient tissues and cancer cell lines. In patient samples, SYT16 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, SYT16 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and UPPER_AERODIGESTIVE_TRACT.
